Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Expert Guidance from the ACR/ARP Access in Rheumatology Meeting

Glen Rodman  |  June 20, 2023

ACR/ARP Access in Rheumatology—As part of ACR Education Exchange 2023, the ACR/ARP Access in Rheumatology meeting addressed some of the major challenges in coverage and payment that U.S. rheumatology practices face.

Speakers included rheumatologists, rheumatology professionals, office managers and CEOs. The first section, Thriving, Not Just Surviving—Keeping Your Rheumatology Practice Solvent, focused on financial management for rheumatology clinics. In the second section, Optimizing Patient Access to Treatment, speakers discussed obstacles to care related to biosimilars, Medicare and prior authorization.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Keep Your Practice Solvent

Mr. Haberkern

The first speaker, Charles Haberkern, MBA, is an entrepreneurial healthcare executive and the CEO of Arthritis, Rheumatic & Bone Disease Associates. In his presentation, Cash Flow Considerations, Mr. Haberkern shared tips from his 25 years of financial experience, advising, “You have to take care of patients first, but if you’re losing money, you can’t take care of patients.”

Mr. Haberkern advised his audience to set aside money to pay invoices when they come due—rather than right away—so the funds can accrue interest while in the bank.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Nehad Soloman, MD, FACR, is a Phoenix-based rheumatologist, a recipient of multiple awards for research and academic excellence and a public speaker for the Arthritis Foundation. In his presentation, Dr. Soloman brought the perspective of both administrator and physician to his analysis of the buy-and-bill model used by infusion centers. Under the buy-and-bill model, healthcare providers purchase certain medicines that require special handling and storage and store them at their practices until they are needed by a patient. Medicare then reimburses physicians for these therapies.

Dr. Soloman

Dr. Soloman emphasized the utility of observing metrics to understand the roles of every person on a team and ensure each person is responsible for their own role. He underscored the importance of resource and inventory management in infusion clinics and advised practices to keep track of drugs by doctor and by quarter to ensure resources are distributed without disparities.

Christopher Phillips, MD, the final speaker of the first session, is a rheumatologist affiliated with Mercy Health-Lourdes Hospital, Paducah, Ky. He delivered a presentation on how to operate a successful infusion clinic. He cautioned against making “bad assumptions”—for example, assuming that a practice’s infusion nurse will never leave that practice. “If you only have one person you rely upon, that person is … more of a key employee than you are to your practice’s survival,” so make sure your pay is competitive and your employees’ needs are met, Dr. Phillips advised.

Dr. Phillips

Additionally, he recommended delegating tasks to nurse practitioners within the parameters of what is legal in each state, as well as insuring drugs in case of a power outage or other emergency. Dr. Phillips emphasized the necessity of being prepared for contingencies and never infusing without a clinician on site.

As with the two preceding speakers, Dr. Phillips recommended keeping a close watch on drug prices, to buy in bulk when prices are low and not to hesitate to negotiate or switch vendors.

Optimize Patient Access to Treatment

Colin Edgerton, MD, RhMSUS, opened the second session with a presentation about biosimilars. Dr. Edgerton is a founding member of Articularis Healthcare, one of the largest rheumatology practices in the U.S., spanning the states of South Carolina and Georgia. Biosimilars can be a great option for patients and can make treatment more financially accessible, he said. In his experience, patients adhere to their medication regimens equally regardless of whether the drug is the originator or a biosimilar, and the efficacy of the drug itself is not reduced.

Dr. Edgerton identified some challenges related to the use of biosimilars, such as complications with prior authorization and clinical concern regarding multiple prescription switches.

“We don’t want a patient getting changed to another adalimumab every quarter or two,” said Dr. Edgerton. Multiple switches in medications may even cause a nocebo effect for patients, who may be understandably confused or anxious about having to adjust to a new drug.

Mr. Turkas

Nicholas Turkas, MS, is the senior director of patient education and community connections for the Arthritis Foundation. Mr. Turkas’s presentation explored the pros and cons of original Medicare vs. Medicare Advantage plans. Original Medicare is a fee-for-service program, which means there is a set, non-negotiable price for any given procedure. Medicare Advantage, however, is managed care, which requires patients to use a limited network of providers and has stricter rules around prior authorization. When patients near age 65, Mr. Turkas recommends having a discussion with them about switching to Medicare, which has “huge implications in terms of access to care.”

Patients may be drawn to Medicare Advantage plans because of the lower up-front cost and such benefits as gym memberships. Medicare Advantage plans may also offer coverage for some care that original Medicare does not, such as vision, dental or hearing. However, the limitations of Medicare Advantage may make care much more expensive for patients switching from original Medicare, and because plan coverage specifics change from year to year, patients may not always be able to see the same doctor.

“It’s important to understand that covered doesn’t mean affordable,” said Mr. Turkas. He also warned that once a patient has switched from original Medicare to a Medicare Advantage plan, it is “almost impossible” to switch back.

Ms. Owen

Michelle Owen, a rheumatology office manager in Portland, Maine, with 15 years of experience, delivered the final presentation, addressing prior authorization. “I am the person who sits across from the patient to try to explain why their particular drug is not approved,” she said.

Ms. Owen strongly advised providers to have a designated person in the office to handle all prior authorizations and to institute a process for automatic appeal for every prior authorization request that is denied.

She reminded the audience that physicians must write a detailed note on behalf of their patient for a prior authorization to go through. “If you’re willing to fight for it, I can get it … but I can’t get it if you don’t give me a good note,” said Ms. Owen.

Conclusion

Speakers at the ACR/ARP Access in Rheumatology meeting presented expert guidance on how to avoid or mitigate some of the field’s significant barriers to access, with information on biosimilars, navigating prior authorization, the buy-and-bill model and more.


Glen K. Rodman is the assistant editor of The Rheumatologist.

Page: 1 2 3 | Multi-Page
Share: 

Filed under:Meeting ReportsPractice Support Tagged with:Access in Rheumatologyfinancial planninghealthcare access

Related Articles
    Georgia Bonney

    Prior Authorization Woes: Barriers to & Delays in Care, Administrative Hassles & Potential Solutions

    August 6, 2021

    As insurers phase out pandemic-related flexibilities, many are raising new obstacles to try to limit their financial exposure.

    Marching to the Biosimilar Beat: Questions on Rollout Remain

    September 7, 2023

    The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

    Dr. Chris Phillips Competes in Triathlons

    October 18, 2018

    “I think I’m mentally sharper when I have been exercising and taking care of myself,” says Chris Phillips, MD, a rheumatologist in solo practice in Paducah, Ky. Dr. Phillips has recognized these benefits since high school, when he began participating in competitive sports. Four years ago, Dr. Phillips was competing against 40 other cyclists in…

    Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?

    October 17, 2017

    Right: The small molecule structure of aspirin (21 molecules). Left: A monoclonal antibody made up of 10,000–20,000 molecules. DNA Illustrations / Science Source As questions about biosimilar medications swirl among U.S. rheumatologists, a recently released report sheds some light on the European experience with biosimilars—and may offer some important insights for the U.S. market. The…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences